Home  »  Science   »  Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares ...

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Are Up 54.71% From The Lows, But Can They Stay Up?

In last trading session, Adaptimmune Therapeutics plc (NASDAQ:ADAP) saw 0.43 million shares changing hands with its beta currently measuring 2.06. Company’s recent per share price level of $2.23 trading at -$0.21 or -8.61% at ring of the bell on the day assigns it a market valuation of $363.80M. That closing price of ADAP’s stock is at a discount of -94.62% from its 52-week high price of $4.34 and is indicating a premium of 54.71% from its 52-week low price of $1.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.77 million shares which gives us an average trading volume of 495.13K if we extend that period to 3-months.

For Adaptimmune Therapeutics plc (ADAP), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.24 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Adaptimmune Therapeutics plc (NASDAQ:ADAP) trade information

Upright in the red during last session for losing -8.61%, in the last five days ADAP remained trading in the red while hitting it’s week-highest on Tuesday, 11/22/22 when the stock touched $2.23 price level, adding 12.2% to its value on the day. Adaptimmune Therapeutics plc’s shares saw a change of -40.53% in year-to-date performance and have moved -5.11% in past 5-day. Adaptimmune Therapeutics plc (NASDAQ:ADAP) showed a performance of 75.59% in past 30-days. Number of shares sold short was 3.71 million shares which calculate 9.98 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $5.33 to the stock, which implies a rise of 58.16% to its current value. Analysts have been projecting $2.00 as a low price target for the stock while placing it at a high target of $10.00. It follows that stock’s current price would drop -348.43% in reaching the projected high whereas dropping to the targeted low would mean a gain of 10.31% for stock’s current value.

Adaptimmune Therapeutics plc (ADAP) estimates and forecasts

Statistics highlight that Adaptimmune Therapeutics plc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 50.68% of value to its shares in past 6 months, showing an annual growth rate of -7.84% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 20.00% in the current quarter and calculating -12.50% decrease in the next quarter. This year revenue growth is estimated to rise 174.40% from the last financial year’s standing.

8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $4.04 million for the same. And 8 analysts are in estimates of company making revenue of $4.06 million in the next quarter that will end on Dec 2022. Company posted $1.2 million and $1.42 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 235.80% while estimating it to be 186.50% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -0.10% during past 5 years. In 2022, company’s earnings growth rate is likely to be around -11.10% while estimates for its earnings growth in next 5 years are of 1.00%.

ADAP Dividends

Adaptimmune Therapeutics plc is more likely to be releasing its next quarterly report on November 08 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Adaptimmune Therapeutics plc (NASDAQ:ADAP)’s Major holders

Insiders are in possession of 0.17% of company’s total shares while institution are holding 70.53 percent of that, with stock having share float percentage of 70.65%. Investors also watch the number of corporate investors in a company very closely, which is 70.53% institutions for Adaptimmune Therapeutics plc that are currently holding shares of the company. Matrix Capital Management is the top institutional holder at ADAP for having 38.97 million shares of worth $66.26 million. And as of Jun 29, 2022, it was holding 23.86% of the company’s outstanding shares.

The second largest institutional holder is NEA Management Company, LLC, which was holding about 17.08 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 10.46% of outstanding shares, having a total worth of $29.04 million.

On the other hand, Old Westbury Small & Mid Cap Strategies Fund and iShares NASDAQ Biotechnology ETF are the top two Mutual Funds which own company’s shares. As of Jul 30, 2022, the former fund manager was holding 2.42 million shares of worth $4.48 million or 1.48% of the total outstanding shares. The later fund manager was in possession of 0.83 million shares on Sep 29, 2022, making its stake of worth around $0.89 million in the company or a holder of 0.51% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts